ABIVAX press release
Abivax presents its 2023 half-year financial results.
Abivax SA, a clinical-stage biotechnology company focused on developing therapeutic treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients suffering from chronic inflammatory diseases, today presents its half-year financial results 2023. The accounts for the first half of 2023, approved by the Board of Directors of the Company on September 19, 2023, have been reviewed, and the certification report is being prepared by the Company’s external auditors.